HLIO director receives 914 RSUs; ownership rises to 26,252 shares
Helios Technologies (HLIO) director Douglas Britt received 914 restricted stock units that vested on 10/04/2025, resulting in the acquisition of 914 shares at no cash cost.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Helios Technologies (HLIO) director Douglas Britt received 914 restricted stock units that vested on 10/04/2025, resulting in the acquisition of 914 shares at no cash cost. The filing reports a transaction price of $52.77, which appears to be the reported market price for reference, and shows Mr. Britt's total beneficial ownership rising to 26,252 shares.
The Form 4 was filed by an attorney-in-fact and indicates the awards are standard restricted stock units that convert to common shares upon vesting with no expiration. No derivative securities remain owned following this transaction.
Positive
- Director alignment: Vesting of 914 RSUs increases director's stake to 26,252 shares, aligning incentives
- Clear settlement: RSUs convert to common stock upon vesting with no expiration, simplifying ownership structure
Negative
- None.
Insights
Director received vested RSUs, modestly increasing ownership.
The transaction documents the vesting and settlement of 914 RSUs into common stock on 10/04/2025, raising reported direct holdings to 26,252 shares. RSUs settled at $0 exercise cost are typical for grant vesting and reflect compensation rather than an open-market purchase.
This increases the director's stake marginally and aligns his economic interest with shareholders; monitor future filings for additional grants or open-market trades within the next 12 months to assess ongoing insider alignment.
Filing shows a standard non‑cash issuance; no outstanding derivatives remain.
The Form 4 lists a non‑derivative acquisition code M for 914 shares and a corresponding RSU entry showing 914 underlying shares with $0 price, leaving 0 derivative securities post-transaction. The reported market price $52.77 is included for reference in the non-derivative line.
Because this reflects vesting settlement (not an open-market trade), it has limited immediate market impact; follow-up filings within the next few weeks could show any subsequent disposition or sales subject to trading plans.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 914 | $0.00 | $0.00 |
| Exercise | Common Stock | 914 | $52.77 | $48K |
Footnotes (1)
- F1. Each RSU represents the right to receive, following vesting, one share of Common Stock. Upon vesting, there is no expiration.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did HLIO director Douglas Britt report on Form 4?
Was the acquisition a market purchase or RSU settlement for HLIO (HLIO)?
What is the reported reference price in the filing?
Are there any derivative securities remaining after this transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.